Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So if I am correct by the end of this year it will be as serious as the beginning of the sales similar to a small test market of the iPod.
Talk about also using DC Vax as a prophylactic prior to surgery has come up. Anyone know if this is for rGBM and vaccine is available or using Direct? Just more revenue to scoop from. Could be why in a Walgreens presentation we got a mention.
If it is market available (UK or everywhere clearly not stated) and NWBO gets about $800 million and you use revenue in a share price calculation multiply by 15 to get share price around Q1 of 2025. I expect $5 to $6 by end of year. Up to $10 by mid 2024 and the following year moving higher.
The market will start looking ahead. I stated this just prior to breaking out of the channel this week.
And as far as EMA next sounds like a guess. Unless he has inside information there has been no public information what their strategy is going forward.
I think the author is saying in the article a potential of 1.4 billion market available to them or revenues expected to NWBO. Not very well written.
So if you are doing $1.4 billion in revenue by 2025. It translates to $10 and up depending on what multiples you give revenue or margins with multiples you want to give earnings.
Is EME a misprint? Does the author mean EMA?
Decent chart. At least we broke out of the channel. This bull wedge was the mother of all wedgies.
Got cut off
Is a lie.
Maybe the shiny apple of your eye. Just want to know when and how much more.
This is like an endless crusade. No one can explain how much more money is needed. Someone in congress yesterday questioned a person giving testimony. A so called expert. The congressman stated if we gave you 50 trillion dollars what can you accomplish. Answer was something like we have to act now!
I just think we deserve the $ figures. Optimistic and pessimistic. Like a normal company provides to shareholders. Years of admission have just been like being told a lie. Direct testing to start shortly comes to mind. These promises evaporate with no explanation. That promise not carried out without an explanation is a lie.
It hasn’t been more valuable other than the history acquired. There are many of us. The history wouldn’t matter if actions and timeframes implied to be taken by management have been not off by a little.
“Weeks turned into years, how quick they pass, and all the stars that never were……” They promised many stars but it has been shareholders “hop in their car and ride away.” More taken for a ride.
$ estimates. Auto correct.
That doesn’t excuse them from reporting expectations and &?estimates to shareholders. Also all aspects of operation estimates that are occurring in OUR company.
No estimates, no analysts and we got more diluted as the years went on.
You keep posting the current share count. All 1.7 billion will be in effect by the time revenue will take over. Anyone doing a guessing game on share price in the next 5 years, the 1.7 is the number.
Gary, you are a good guy but unfortunately we do not know any of this that you posted. You may be spot on, pessimistic or optimistic. No real guidance given on this.
“I really believe they'll wait for the Eden and I really don't believe it willl take that much longer, though I doubt an FDA approval this year. A BLA filing this year should still be possible. “
She speaks and is afraid to take a question from shareholders in a public forum as public companies do.
In the course of a trial you have the option to change the determination prior to DL. By then opinions from practitioners (especially from Liau) had made External Controls enter into guidance of the FDA and it would appear tailored for our trial design.
Doc. You are always reasonable. Let’s just leave it with my last comment. I really do not want to get into it today.
I hope for the best financially for us and finally for this company to grow up into a properly functioning entity with shareholders.
If a partner came in they could have continued to use Cognate for L. The problem was governance issues having the SEC making Linda part ways in her ownership of Cognate. Not the use of Cognate. A partner would have expanded that. And I contend Direct would be selling years before now. The product does not need the Eden system and the same type of processing.
Sorry, do not trust Linda. Saying they almost lost the company and giving no details of the hostile takeover provides zero confidence about how true it was or who it was. She was in danger, I am not sure we were in any way.
I expect more than $60 with all solid tumors but we lost 3 to 4X our final outcome based on her actions. You can say look forward and forget what happened. I refuse to because I disagree because she was trued up with shares even with poor performance.
We just disagree. I can see a $300 stock when before I could see a final outcome of over $1000 share price. Without all the averaging down we had to do and the crazy drama. Created by them. An earlier partnership would have stopped the attacks and the crazy share swings and dilutions. I blame her.
I kind of believed that at first but with MRK not taking a position, I have my doubts now. So unless MRK takes a position, I will question it.
I averaged down as well, forced to based on bad decisions by management, but May 10 was a disaster for me. Brought me below my average. And I sure would not have bought more above a dollar without how bad their guidance of how things were going to go the last 3 to 4 years.
We would not be trading at 60 cents today but higher than $60. Direct would be selling because the cancers that could be treated would have been much easier. Great, she has a personal thing with the granddad of cancer. My father went that way but there are easier ways to get to our endpoint of share appreciation.
That is my primary goal.
When NWBO had a large investor that kept our stock moving in a positive direction had close ties to AZN and their division in the UK things went south. At this time AZN is #5 In cancer immunotherapy sales. They didn’t have that big a footprint at the timeframe I am talking about. At that time we had about 60 to 80 million shares.
We now have 1.7 billion authorized. If we formed a partnership back then we would have gotten funding for trials and probably have 200 million authorized shares right now. So if we gave up 50% of the profits of money about to be made we would still be about 3 to 4X more profitable than now at this outstanding authorized share count. We surely would not have been attacked in the markets and had analysts following us from then. For sure we would already have been selling Direct at this time. You wouldn’t need to wait five years for the data.
It was framed by Linda that we almost lost the company. I contend that she almost lost her seat as CEO and she doesn’t like to share. In the end, anyone invested during the Woodford period to today, their investment has lost value due to some bad decisions.
Maybe that opportunity was the biggest loss for shareholders vs Duffy.
“If he reviewed all the data, would he sacrifice the once-in-a-life opportunity of being one of the few involved in a cause that may revolutionize the oncology therapeutics?”
You just made my argument. I think there was poor discourse between them and she had control of the BOD. He should have been made CEO. A person that helped bring Keytruda through trials to market. The only guy who had real experience. Others say he was on loan from MRK.
My guess is he wanted to partner. Part of his job description was to look for alliances. So instead of partnering we got loads of authorized shares and Direct still MIA. Maybe a Tissue Agnostic filing includes Direct. Could be why Walgreen’s guy is talking about us. That is something that can be sold through a pharmacy to hospitals. Just spitballing.
“Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of new and updated data from its diverse oncology and hematology pipeline at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 2-6 in Chicago, IL. Data presentations from 10 abstracts will include insights on four approved or investigational treatment regimens, showcasing the expanding potential of Regeneron’s portfolio and commitment to harnessing combination approaches to address the unmet need of patients with difficult-to-treat cancers.”
These guys have analysts and quarterly calls. I think this is where Duffy landed on his feet as well.
Losing Duffy was the biggest loss this company suffered. One can only speculate on the interaction.
Time to put out pessimistic and if things go according to plan optimistic number. You might see some analysts and a rocket ship share price.
Good point.
I still think you can get a share price in the 100s with a treatment for all solid cancer. A few hundred.
But we have been on the 1 yard line for about 9 years. Talk about the longest play in football.
And I still think they can do it alone if filing for agnostic tissue. I would say oncologists would make the pairings they want and university hospitals will want to do research. All we would need to do is provide the product. UCLA ran some combinations. Jonsson in Texas is running a combination trial.
I have been using margins of 50% but I expect them to be much higher.
Like everyone, just so discouraged about the 1 yard line for so many years some think, and not unwise to think this way, for very low expectations and a BO as quickly as possible.
They get UK approval money will start coming in.
Not really investor conference.
Society for Immunotherapy. In San Diego.
I hope they are talking $ before November.
SITC Nov 3 - 5..
An investor conference.
This booth space is for a different conference.
Probably a refresh of the trademark that may need to be done every so many years.
The application says current trademark holder is Northwest Biotherapeutics.
I have owned the shares 11 years. This saga is not all on MMs and short sellers. Some really bad decisions through the years by management.
Hope we are past this and along with GBM they are also filing a tissue agnostic BLA.
They keep adding Sawston personnel so I just do not think they are their yet. They may issue some shares at an inflated price above the price at the time for a percentage of profits with more percentages of ownership with each milestone passing that they can agree on. I do not see a BO. It will not matter to me once any deal is struck.
You would be more accurate if you saw a hostile takeover in the near future. That would start a budding war. At this price NWBO is vulnerable to that scenario.
Doubt it. Happy to be wrong. But I expect shares to start climbing in a month or two.
Anyone saying BO after submission has a head wind. Doubt they would have purchased the booth space with a deal in hand or in close negotiations.
It was not used in Ph III.
Add the Poly ICLC and you get close to a cure. Even though our numbers without were good I am sure RAs will be made aware this vaccine is the foundation of the cure based on early results with the POLY. Wouldn’t be surprised if Ashkan is including the Poly now with the specials.
Not too far from AZN either.
Booth right next to MRK.
Then they should have filed a lawsuit back then instead of being crushed over the years.
All this type of information is digitally stored and could have issued a subpoena.
Wonder why it was a favorite of Woodford?
They claim for the journal. It will get approved for GBM and if QOL means something for NICE pricing then I still think we are in reallygood shape.
They are talking all solid cancers and so is NWBO at their ASCO theater presentation.